Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoViricides Inc. on Panel at the SALSS 2008 Conference in Stockholm

Abstract:
EKC, HIV Results, as well as Broad-Spectrum Nanoviricides Capability Presented

NanoViricides Inc. on Panel at the SALSS 2008 Conference in Stockholm

WEST HAVEN, CT | Posted on August 25th, 2008

anoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), said that Anil R. Diwan, PhD, President of the Company, was a participant in a panel on global pharmaceutical strategies at the Fourth Annual Swedish-American Life Sciences Summit held August 20-22, 2008 in Stockholm, Sweden. Speaking in front of a large pharmaceutical and life sciences finance industry group, he enumerated the accomplishments of the Company. He also presented his thoughts on the Company's global strategy for supplying nanoviricides treatments for serious viral diseases to both developed and developing countries.

Dr. Diwan was invited as a panel member on the panel discussion "Emerging Life Sciences in a Global Context- A New Necessity" held last Friday. After discussing the Company's accomplishments, he spoke about the successes of the nanoviricides technology. In response to a question, he said that the Company has a strong focus on commercially important disease targets such as Influenza, Bird Flu, viral diseases of the eye, HIV, and Hepatitis C. He added that the Company has developed a unique broad-spectrum antiviral technology that can work well against a large number of different viruses. Using such agents, it will be possible to develop cost-effective treatment strategies against lethal diseases of the developing world such as Rabies, Dengue virus, and many others. Many of these diseases are now being seen more frequently in developed countries also.

The Fourth SALSS featured leaders of Life Sciences industry in both Sweden and the United States. This forum brought together key pharmaceutical executives, entrepreneurs, venture capitalists and financiers, and key scientists from both countries in an invitation-only open-discussion format.
(www.marketwatch.com/news/story/swedish-american-life-science-summit-stockholm/story.aspx?guid=%7B0D2BC44F-BFBF-4F8A-ACA8 -55E5DCEAFC45%7D&dist=hppr).

####

About NanoViricides Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

For more information, please click here

Contacts:
NanoViricides, Inc.
Amanda Schuon
310-550-7200

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

University of Tehran Researchers Invent Non-Enzyme Sensor to Detect Blood Sugar April 23rd, 2014

Gold nanoparticles help target, quantify breast cancer gene segments in a living cell April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Nanomedicine

University of Tehran Researchers Invent Non-Enzyme Sensor to Detect Blood Sugar April 23rd, 2014

Gold nanoparticles help target, quantify breast cancer gene segments in a living cell April 23rd, 2014

QuantuMDx announce prototype handheld lab for 15 minute malaria diagnosis and drug resistance testing April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

Announcements

Characterizing inkjet inks: Malvern Instruments presents new rheological research April 23rd, 2014

NanoSafe, Inc. announces the addition of the Labconco Protector® Glove Box to its NanoSafe Tested™ registry April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Events/Classes

Characterizing inkjet inks: Malvern Instruments presents new rheological research April 23rd, 2014

PETA science consortium to present hazard testing strategy at nanotoxicology meeting: High tech field ripe for use of sophisticated non-animal testing strategies April 22nd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

INSCX™ exchange to present Exchange trade reporting mechanism for engineered nanomaterials (NMs) to UK regulation agencies, insurers and upstream/downstream users April 17th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE